Diopter Corp

Diopter Corp was a clinical-stage biotechnology company dedicated to developing transformative therapies for patients suffering from severe ocular surface diseases and neuropathic corneal pain. Founded by Dr. Perry Rosenthal, a pioneer in ophthalmology and the creator of the PROSE treatment, the company focused on addressing the unmet needs of patients with chronic, debilitating eye pain. Their research centered on proprietary topical formulations designed to stabilize the ocular surface and modulate pain signaling in the cornea. Based in Cambridge, Massachusetts, the company sought to provide relief for patients who had exhausted conventional dry eye treatments. Diopter Corp is no longer active, having dissolved following the passing of its founder in 2018. The company's mission was driven by the clinical observation of "pain without stain," a condition where patients experience intense ocular pain despite minimal clinical signs of dry eye.